Table 3.
Response to neoadjuvant therapy assessment
| Total N = 704 | PDAC N = 678 | I-IPMN N = 26 | P value | |
|---|---|---|---|---|
|
NAT response Marked response Partial/No response Undetermined |
203 (29) 367 (52) 22 (3) |
198 (29) 354 (67) 22 (3) |
5 (19) 13 (81) 0 |
0.231 |
| Complete NAT response | 65 (9) | 64 (9) | 1 (4) | 0.322 |
| CA19.9 response | 397/640 (62) | 381/618 (62) | 16/22 (73) | 0.293 |
| Δ in CA19-9 | −65 (4–301) | −68 (5–305) | −21.5 (0–130) | 0.067 |
| PET response | 252/393 (64) | 243/379 (64) | 9/14 (64) | 0.990 |
| Δ in SUV | −2.5 (0.1–4.8) | −2.5 (0.1–4.8) | −3.5 (1.5–4.9) | 0.206 |
|
RECIST criteria Complete response Partial response Stable disease Progressive disease |
19 (3) 218 (31) 363 (52) 48 (7) |
19 (3) 210 (31) 347 (51) 47 (7) |
0 8 (31) 16 (62) 1 (4) |
0.685 |
| RECIST complete/partial response | 237/648 (37) | 229/623 (37) | 8/25 (32) | 0.628 |
| Δ in radiological size | −5 (0–12) | −5 (0–13) | −5 (0–10) | 0.732 |
NAT = neoadjuvant therapy, PDAC = pancreatic ductal adenocarcinoma, I-IPMN = invasive intraductal mucinous cystic neoplasm, PET = positron emission tomography